Effect of Melatonin on Sleep Quality in Patients Dementia
Primary Purpose
Sleep Disorders, Dementia
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Melatonin 5 mg
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Sleep Disorders focused on measuring melatonin, sleep, dementia, cognition
Eligibility Criteria
Inclusion Criteria:
- Older than 60 years;
- Circadian cycle sleep disorder with insomnia (according to Diagnostic and Statistical Manual of Mental Disorders- V criteria);
- Mild or moderate dementia (clinical dementia rating 1 and 2);
- Medications such as anti-depressants, acetylcholinesterase inhibitors, antipsychotics or memantine were allowed as long as they were initiated for over 8 weeks.
Exclusion Criteria:
- They had other diagnoses of sleep disorders, known hypersensitivity to melatonin, use of stimulants or hypnotics, recent diagnosis (within 8 weeks) of mood disorders or neuropsychiatric symptoms.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Placebo Comparator
Arm Label
Melatonin
placebo
Arm Description
Melatonin 5 mg, daily, eight weeks
Placebo, daily, eight weeks
Outcomes
Primary Outcome Measures
Pittsburgh Sleep Quality Index
A self-administered questionnaire that provides an overall rating of sleep quality.
Secondary Outcome Measures
Minimental test
The original purpose is to allow physicians to standardize and quantify cognitive status.
Full Information
NCT ID
NCT03066518
First Posted
February 19, 2017
Last Updated
February 23, 2017
Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
1. Study Identification
Unique Protocol Identification Number
NCT03066518
Brief Title
Effect of Melatonin on Sleep Quality in Patients Dementia
Official Title
A Randomized Placebo-controlled Trial Evaluating the Effect of Melatonin on Sleep Quality in Patients With Dementia
Study Type
Interventional
2. Study Status
Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
January 15, 2016 (Actual)
Primary Completion Date
January 25, 2017 (Actual)
Study Completion Date
January 25, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Introduction: Patients with dementia may suffer from poor sleep quality. Disturbance in the metabolism melatonin may have a role in the pathogenesis of sleep-wake cycle alterations in dementia.
Objective: To evaluate the efficacy of low dose exogenous melatonin in improving sleep quality.
Design: A single-center randomized, double-blinded, placebo-controlled study carried out on outpatients with dementia and sleep alterations.
Participants: The investigators calculated a 40 individuals aged 65 years or over with a diagnosis of mild-moderate dementia (Clinical Dementia Rating 1-2).
Intervention: Patients were randomized to receive either 5 mg of melatonin or placebo every night for 8 weeks.
Measurements: The primary outcome was sleep quality according to the Pittsburgh Sleep Quality Index (PSQI).
Detailed Description
This is a single-center study. The study protocol, informed consents, and amendments were approved in writing by the appropriate local site Independent Ethics Committee (IEC)/Institutional Review Boards (IRB) (Ethics Committee of the Universidad Autónoma de Nuevo León, School of Medicine).
The patients were recruited as outpatients from the Geriatrics Clinic. A total of 67 patients were screened out of which 40 male and female patients diagnosed with mild to moderate dementia were recruited to the study. Following inclusion, all patients underwent randomization to treatment with melatonin (5 mg orally) or placebo for 8 weeks. To prevent bias, matching placebo tablets, which were identical in appearance, taste, and odor, were used. The treatment was double-blinded, with two parallel treatment groups. Selection for a treatment group was determined by a computer-generated randomization list, in a 1:1 ratio using the randomized permuted blocks method.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Disorders, Dementia
Keywords
melatonin, sleep, dementia, cognition
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
A randomized, double-blinded, placebo-controlled study
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Selection for a treatment group was determined by a computer-generated randomization list, in a 1:1 ratio using the randomized permuted blocks method.
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Melatonin
Arm Type
Placebo Comparator
Arm Description
Melatonin 5 mg, daily, eight weeks
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
Placebo, daily, eight weeks
Intervention Type
Drug
Intervention Name(s)
Melatonin 5 mg
Other Intervention Name(s)
Benedorm
Intervention Type
Other
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Pittsburgh Sleep Quality Index
Description
A self-administered questionnaire that provides an overall rating of sleep quality.
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Minimental test
Description
The original purpose is to allow physicians to standardize and quantify cognitive status.
Time Frame
baseline and to the 8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
95 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Older than 60 years;
Circadian cycle sleep disorder with insomnia (according to Diagnostic and Statistical Manual of Mental Disorders- V criteria);
Mild or moderate dementia (clinical dementia rating 1 and 2);
Medications such as anti-depressants, acetylcholinesterase inhibitors, antipsychotics or memantine were allowed as long as they were initiated for over 8 weeks.
Exclusion Criteria:
They had other diagnoses of sleep disorders, known hypersensitivity to melatonin, use of stimulants or hypnotics, recent diagnosis (within 8 weeks) of mood disorders or neuropsychiatric symptoms.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guillermo Guajardo, MD
Organizational Affiliation
HUGonzález
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
21225347
Citation
Crowley K. Sleep and sleep disorders in older adults. Neuropsychol Rev. 2011 Mar;21(1):41-53. doi: 10.1007/s11065-010-9154-6. Epub 2011 Jan 12.
Results Reference
background
PubMed Identifier
19738366
Citation
Neikrug AB, Ancoli-Israel S. Sleep disorders in the older adult - a mini-review. Gerontology. 2010;56(2):181-9. doi: 10.1159/000236900. Epub 2009 Sep 9.
Results Reference
background
PubMed Identifier
19426575
Citation
Beaulieu-Bonneau S, Hudon C. Sleep disturbances in older adults with mild cognitive impairment. Int Psychogeriatr. 2009 Aug;21(4):654-66. doi: 10.1017/S1041610209009120. Epub 2009 May 11.
Results Reference
background
PubMed Identifier
21417189
Citation
Woods DL, Phillips LR, Martin JL. Biological basis for sleep disturbance and behavioral symptoms in dementia: a biobehavioral model. Res Gerontol Nurs. 2011 Oct;4(4):281-93. doi: 10.3928/19404921-20110302-01. Epub 2011 Mar 16.
Results Reference
background
PubMed Identifier
26742676
Citation
Guarnieri B, Cerroni G, Sorbi S. Sleep disturbances and cognitive decline: recommendations on clinical assessment and the management. Arch Ital Biol. 2015 Jun-Sep;153(2-3):225-30. doi: 10.12871/0003982920152347.
Results Reference
background
PubMed Identifier
27476067
Citation
Ooms S, Ju YE. Treatment of Sleep Disorders in Dementia. Curr Treat Options Neurol. 2016 Sep;18(9):40. doi: 10.1007/s11940-016-0424-3.
Results Reference
background
PubMed Identifier
25614508
Citation
Xu J, Wang LL, Dammer EB, Li CB, Xu G, Chen SD, Wang G. Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2015 Aug;30(5):439-47. doi: 10.1177/1533317514568005.
Results Reference
background
PubMed Identifier
27851868
Citation
McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2016 Nov 16;11(11):CD009178. doi: 10.1002/14651858.CD009178.pub3.
Results Reference
background
PubMed Identifier
25515275
Citation
Chien MY, Chen HC. Poor sleep quality is independently associated with physical disability in older adults. J Clin Sleep Med. 2015 Mar 15;11(3):225-32. doi: 10.5664/jcsm.4532.
Results Reference
background
PubMed Identifier
33189083
Citation
McCleery J, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2020 Nov 15;11(11):CD009178. doi: 10.1002/14651858.CD009178.pub4.
Results Reference
derived
PubMed Identifier
34674490
Citation
Morales-Delgado R, Camara-Lemarroy CR, Salinas-Martinez R, Gamez-Trevino D, Arredondo-Jaime A, Hernandez-Maldonado E, Guajardo-Alvarez G. A randomized placebo-controlled trial evaluating the effect of melatonin on sleep quality in patients with mild-moderate dementia. Eur Geriatr Med. 2018 Aug;9(4):449-454. doi: 10.1007/s41999-018-0068-9. Epub 2018 May 24.
Results Reference
derived
Learn more about this trial
Effect of Melatonin on Sleep Quality in Patients Dementia
We'll reach out to this number within 24 hrs